VE-PTP Extracellular Domain Antibodies Delivered by a Gene Therapy Vector
The disclosure provides compositions and methods for the treatment of ocular conditions associated with angiogenesis, comprising administering a nucleic acid that encodes for a tyrosine phosphatase suppressor to a subject.
1 . A pharmaceutical composition comprising a nucleic acid, wherein the nucleic acid is carried by a vector, wherein the nucleic acid encodes a tyrosine phosphatase suppressor.
2 . The pharmaceutical composition of claim 1 , wherein the tyrosine phosphatase is HPTPβ.
3 . The pharmaceutical composition of claim 1 , wherein the tyrosine phosphatase suppressor is a monoclonal antibody or an antigen-binding fragment thereof.
4 . The pharmaceutical composition of claim 1 , wherein the vector is a viral vector.
5 . The pharmaceutical composition of claim 4 , wherein the viral vector is an adenovirus-associated viral vector.
6 . The pharmaceutical composition of claim 1 , wherein the tyrosine phosphatase suppressor binds an extracellular domain of HPTPβ.
7 . The pharmaceutical composition of claim 1 , wherein the tyrosine phosphatase suppressor binds the first FN3 repeat of an extracellular domain of HPTPβ.
8 . The pharmaceutical composition of claim 6 , wherein the tyrosine phosphatase suppressor binds a sequence with at least 90% homology to SEQ ID NO.: 17.
9 . The pharmaceutical composition of claim 3 , wherein the monoclonal antibody or the antigen-binding fragment thereof comprises a heavy chain variable region having at least 90% homology to SEQ ID NO.: 1.
10 . The pharmaceutical composition of claim 3 , wherein the monoclonal antibody or the antigen-binding fragment thereof comprises a light chain variable region having at least 90% homology to SEQ ID NO.: 4.
11 . The pharmaceutical composition of claim 3 , wherein the monoclonal antibody or the antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region has at least 90% homology to SEQ ID NO.: 1 and the light chain variable region has at least 90% homology to SEQ ID NO.: 4.
12 . The pharmaceutical composition of claim 1 , the pharmaceutical composition further comprising a pharmaceutically-acceptable excipient, wherein the pharmaceutical composition is in a unit dosage form.
13 . The pharmaceutical composition of claim 1 , comprising from about 1 ng to about 1 mg of the vector.
14 . A pharmaceutical composition comprising a nucleic acid, wherein the nucleic acid is carried by a vector, wherein the nucleic acid encodes a Tie2 activator.
15 . The pharmaceutical composition of claim 14 , wherein the vector is a viral vector.
16 . The pharmaceutical composition of claim 15 , wherein the viral vector is an adenovirus-associated viral vector.
17 . The pharmaceutical composition of claim 14 , wherein the Tie2 activator is a monoclonal antibody or an antigen-binding fragment thereof.
18 . The pharmaceutical composition of claim 17 , wherein the monoclonal antibody or antigen-binding fragment thereof binds to a tyrosine phosphatase.
19 . The pharmaceutical composition of claim 18 , wherein the tyrosine phosphatase is HPTPβ.
20 . The pharmaceutical composition of claim 14 , wherein the Tie2 activator binds an extracellular domain of HPTPβ.
21 . The pharmaceutical composition of claim 14 , wherein the Tie2 activator binds the first FN3 repeat of an extracellular domain of HPTPβ.
22 . The pharmaceutical composition of claim 20 , wherein the Tie2 activator binds a sequence with at least 90% homology to SEQ ID NO.: 17.
23 . The pharmaceutical composition of claim 17 , wherein the monoclonal antibody or the antigen-binding fragment thereof comprises a heavy chain variable region having at least 90% homology to SEQ ID NO.: 1.
24 . The pharmaceutical composition of claim 17 , wherein the monoclonal antibody or the antigen-binding fragment thereof comprises a light chain variable region having at least 90% homology to SEQ ID NO.: 4.
25 . The pharmaceutical composition of claim 17 , wherein the monoclonal antibody or the antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region has at least 90% homology to SEQ ID NO.: 1 and the light chain variable region has at least 90% homology to SEQ ID NO.: 4.
26 . The pharmaceutical composition of claim 14 , the pharmaceutical composition further comprising a pharmaceutically-acceptable excipient, wherein the pharmaceutical composition is in a unit dosage form.
27 . The pharmaceutical composition of claim 14 , comprising from about 1 ng to about 1 mg of the vector.